

# Multicentre, randomised, double-blind, placebo-controlled, parallel-group comparison in order to prove efficacy and tolerability of cineole in the long-term treatment of patients with chronic obstructive pulmonary disease (COPD)

<b>Submission date</b> 15/10/2008	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 27/10/2008	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 30/07/2009	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Prof Heinrich Worth

**Contact details**  
Medizinische Klinik I  
Klinikum Fürth  
Fürth  
Germany  
90766  
+49 (0)911 75801101  
med1@klinikum-fuerth.de

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**

K/588

## **Study information**

**Scientific Title**

### **Study objectives**

Concomitant cineole therapy in addition to basic treatment will reduce exacerbations in patients with chronic obstructive pulmonary disease (COPD).

### **Ethics approval required**

Old ethics approval format

### **Ethics approval(s)**

1. Ethics Committee of Bayerische Landesärztekammer, Muenchen, approved on 11th September 2003
2. Medical Association Nordrhein, Duesseldorf, approved on 11th November 2003
3. Medical Association Westfalen-Lippen, Muenster, approved on 18th September 2003
4. Medical Association Hessen, Frankfurt, approved on 2nd October 2003
5. Medical Association Hamburg, approved on 12th September 2003
6. Ethics Committee of Sächsische Landesärztekammer, Dresden, approved on 15th December 2003

### **Study design**

Multicentre randomised double-blind placebo-controlled parallel-group trial

### **Primary study design**

Interventional

### **Secondary study design**

Randomised controlled trial

### **Study setting(s)**

Not specified

### **Study type(s)**

Treatment

### **Participant information sheet**

### **Health condition(s) or problem(s) studied**

Chronic obstructive pulmonary disease (COPD)

### **Interventions**

Cineole 200 mg (oral) three times per day in addition to basic treatment, for 6 months during winter. Control group received placebo capsules.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Cineole

**Primary outcome measure**

Difference between exacerbations (number, time, severity).

The primary and secondary outcomes were assessed at initial visit and after 1, 2, 3, 4, 5 and 6 months of treatment.

**Secondary outcome measures**

1. Symptoms of COPD (dyspnoea, secretion, cough)
2. Spirometry: FEV1, forced vital capacity (FVC), vital capacity (VC)
3. Quality of life, assessed by the St George's Respiratory Questionnaire (SGRQ)

The primary and secondary outcomes were assessed at initial visit and after 1, 2, 3, 4, 5 and 6 months of treatment.

**Overall study start date**

26/09/2003

**Completion date**

06/07/2005

**Eligibility****Key inclusion criteria**

1. Patients (both males and females) with COPD, at least three exacerbations during the winter months
2. Forced expiratory volume in 1 second (FEV1) greater than 30% and less than 70% of predicted value, increase of FEV1 less than 15% and less than 200 ml after inhalation of beta-agonists
3. Smoker/ex-smoker greater than 10 pack years

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

240

**Key exclusion criteria**

1. Aged less than 40 years and greater than 80 years
2. Asthma bronchiale
3. Comedication with other mucolytics
4. Infection at the beginning of the study

**Date of first enrolment**

26/09/2003

**Date of final enrolment**

06/07/2005

**Locations****Countries of recruitment**

Germany

**Study participating centre**

Medizinische Klinik I

Fürth

Germany

90766

**Sponsor information****Organisation**

MKL Institute of Clinical Research (MKL Institut für Klinische Forschung GmbH) (Germany)

**Sponsor details**

c/o Dr Uwe Dethlefsen

Pauwelsstr. 19

Aachen

Germany

52074

+49 (0)241 9632121

MKLKLIFO@t-online.de

**Sponsor type**

Industry

**Funder(s)**

Funder type

Industry

### Funder Name

Cassella-med GmbH & Co. KG. (Germany)

## Results and Publications

### Publication and dissemination plan

Not provided at time of registration

### Intention to publish date

### Individual participant data (IPD) sharing plan

### IPD sharing plan summary

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	22/07/2009		Yes	No